Bicara CEO exercises options, sells 10K shares
Bicara Therapeutics Inc. director and Chief Executive Officer Claire Mazumdar reported option exercises and stock sales dated August 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Bicara Therapeutics Inc. director and Chief Executive Officer Claire Mazumdar reported option exercises and stock sales dated August 10, 2026. She exercised 10,000 stock options at an exercise price of $3.7898 per share, acquiring 10,000 shares of common stock, and then sold 10,000 common shares at a weighted average price of $27.975 per share in multiple transactions. After the exercise, she directly held 110,546 stock options linked to this grant, which expires on April 5, 2033. These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,000 shares ($242K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Mazumdar Claire
Role
Chief Executive Officer
Sold
10,000 shs ($280K)
Approx. gross sale proceeds
$280K
Approx. exercise cost
$38K
Approx. pre-tax spread
$242K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F3 | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 10,000 | $3.7898 | $38K |
| Sale | Common Stock F1, F2 | 10,000 | $27.975 | $280K |
Holdings After Transaction:
Stock Option (Right to Buy) — 110,546 contracts (Direct);
Common Stock — 362,152 shares (Direct)
Footnotes (3)
- F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.58 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3. The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Option shares exercised: 10,000 shares
Option exercise price: $3.7898 per share
Shares sold: 10,000 shares
+4 more
7 metrics
Option shares exercised
10,000 shares
Stock Option (Right to Buy) exercised on August 10, 2026
Option exercise price
$3.7898 per share
Exercise price for 10,000 stock options
Shares sold
10,000 shares
Common stock sales on August 10, 2026
Weighted average sale price
$27.975 per share
Weighted average price for 10,000 common shares sold
Remaining options in this grant
110,546 options
Total stock options following the reported exercise
Option expiration date
April 5, 2033
Expiration date of the exercised stock option grant
10b5-1 plan adoption date
March 31, 2026
Date the Rule 10b5-1 trading plan was adopted
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), vesting, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
vesting financial
"shares underlying this option vest in sixteen equal quarterly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
common stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Bicara Therapeutics (BCAX) report for Claire Mazumdar?
Claire Mazumdar reported exercising 10,000 stock options at $3.7898 per share and selling 10,000 common shares at a weighted average price of $27.975 on August 10, 2026.
Were Claire Mazumdar’s BCAX trades made under a Rule 10b5-1 plan?
Yes. The filing states the transactions were executed under a Rule 10b5-1 trading plan adopted on March 31, 2026, indicating they were pre-arranged rather than discretionary trades.
What option grant did Claire Mazumdar exercise in the BCAX Form 4?
She exercised a Stock Option (Right to Buy) covering 10,000 shares of common stock at an exercise price of $3.7898 per share, from an option expiring on April 5, 2033 with 110,546 options remaining afterward.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates